Rockefeller Capital Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$926K Buy
1,562
+239
+18% +$119K ﹤0.01% 1645
2025
Q4
$645K Buy
1,323
+127
+11% +$59.1K ﹤0.01% 1767
2025
Q3
$501K Buy
+1,196
New +$402K ﹤0.01% 1763
2023
Q2
Sell
-900
Closed -$200K 2031
2023
Q1
$200K Sell
900
-44
-5% -$10.8K ﹤0.01% 1818
2022
Q4
$262K Buy
944
+150
+19% +$37.9K ﹤0.01% 1541
2022
Q3
$166K Buy
794
+465
+141% +$104K ﹤0.01% 1730
2022
Q2
$76K Buy
329
+65
+25% +$13.2K ﹤0.01% 2092
2022
Q1
$47K Buy
264
+10
+4% +$1.91K ﹤0.01% 2334
2021
Q4
$54K Buy
254
+180
+243% +$35.3K ﹤0.01% 2188
2021
Q3
$13K Sell
74
-825
-92% -$163K ﹤0.01% 2783
2021
Q2
$161K Sell
899
-14
-2% -$2.67K ﹤0.01% 1599
2021
Q1
$152K Buy
913
+72
+9% +$12K ﹤0.01% 1428
2020
Q4
$127K Buy
841
+16
+2% +$2.1K ﹤0.01% 1353
2020
Q3
$83K Sell
825
-300
-27% -$32.9K ﹤0.01% 1334
2020
Q2
$136K Buy
1,125
+300
+36% +$33.8K ﹤0.01% 1066
2020
Q1
$78K Hold
825
﹤0.01% 1098
2019
Q4
$73K Hold
825
﹤0.01% 1054
2019
Q3
$66K Buy
+825
New +$66.4K ﹤0.01% 899
2019
Q2
Sell
-251
Closed -$29K 1989
2019
Q1
$29K Buy
+251
New +$29.2K ﹤0.01% 1102

Other funds holding UTHR

Rockefeller Capital Management's UTHR Position: Q1 2026 in Review

Rockefeller Capital Management increased its United Therapeutics (UTHR) stake by 18% in Q1 2026, buying an estimated $119K and bringing the position to 1,562 shares worth $926K. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Rockefeller Capital Management first reported a position in UTHR in Q1 2019 and has held it in 19 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Rockefeller Capital Management held 1,562 shares of United Therapeutics worth $926K as of Q1 2026.
  • Rockefeller Capital Management bought 239 United Therapeutics shares in Q1 2026, an estimated $119K.
  • United Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1645 holding.
  • Rockefeller Capital Management first reported a position in United Therapeutics in Q1 2019 and has held it in 19 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.